COMBINATION OF A MAPK/ERK PATHWAY INHIBITOR AND A GLYCOSAMINOGLYCAN FOR THE TREATMENT OF CANCER

摘要

A negatively charged glycosaminoglycan is provided for use as a medicament for the treatment of cancer A combined administration of a negatively charged glycosaminoglycan is provided in which the glycosaminoglycan is characterised by the absence of the terminal pentasaccharide of Heparin, and an inhibitor of the MAPK/ERK pathway. A combined administration of a glycosaminoglycan and a MAPK/ERK pathway inhibitor is provided as a medicament for the treatment of cancer types that exhibit a resistance towards a single MAPK/ERK pathway inhibitor treatment.